Aclaris Net Income from 2010 to 2024
| ACRS Stock | USD 3.82 0.19 5.23% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -11 M | Current Value -7.6 M | Quarterly Volatility 13 M |
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
Aclaris | Net Income |
Latest Aclaris Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aclaris Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aclaris Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aclaris Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aclaris Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (88.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aclaris Net Income Regression Statistics
| Arithmetic Mean | (58,513,137) | |
| Coefficient Of Variation | (84.57) | |
| Mean Deviation | 42,513,079 | |
| Median | (51,154,000) | |
| Standard Deviation | 49,482,166 | |
| Sample Variance | 2448.5T | |
| Range | 137.6M | |
| R-Value | (0.78) | |
| Mean Square Error | 1023.1T | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | (8,655,741) | |
| Total Sum of Squares | 34278.8T |
Aclaris Net Income History
Other Fundumenentals of Aclaris Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Aclaris Therapeutics Net Income component correlations
About Aclaris Therapeutics Financial Statements
Aclaris Therapeutics shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | -78.2 M | -82.1 M | |
| Net Loss | (1.27) | (1.33) | |
| Net Income Per E B T | 1.00 | 1.19 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.